TransMedics Group announced a 21% increase in Q1 2026 revenue to $173.9 million and net income of $7.3 million, driven by higher use of its Organ Care System and logistics services. Despite increased operating expenses and lower operating margins due to investments in growth and supply chain costs, the company reaffirmed its full-year 2026 revenue guidance of $727 million to $757 million, expecting 20-25% growth. TransMedics is focused on expanding its heart and lung transplant programs in the U.S. and Europe and advancing its kidney transplant technology to drive future growth and improve access to organ transplants globally.
TransMedics saw its stock drop nearly 50% in 2026 after missing Q1 earnings estimates despite 21% revenue growth to $174 million, driven by strong liver segment sales. Higher costs squeezed margins and net income, but management maintains 2026 revenu...
TransMedics Group, a medical tech company specializing in organ transplant therapies, granted stock options for 37,367 shares and 24,848 restricted stock units to 14 new employees on May 19, 2026. These grants serve as inducements for employment and ...
